Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Sibbing, T. Morath, Julia Stegherr, S. Braun, W. Vogt, M. Hadamitzky, A. Schömig, A. Kastrati, N. Beckerath (2009)
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrelThrombosis and Haemostasis, 101
NDA 20–839 S-044.
R. Sacco, R. Adams, V. Chair, G. Albers, M. Alberts, O. Benavente, K. Furie, L. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, S. Johnston, I. Katzan, M. Kelly‐Hayes, E. Kenton, M. Marks, L. Schwamm, Thomas Tomsick (2006)
Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: theStroke, 37 2
N. Abraham, M. Hlatky, E. Antman, Deepak Bhatt, D. Bjorkman, C. Clark, C. Furberg, David Johnson, Charles Kahi, L. Laine, K. Mahaffey, E. Quigley, J. Scheiman, L. Sperling, G. Tomaselli (2010)
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID UseThe American Journal of Gastroenterology, 105
Sanofi patent on Plavix. Reuters
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont, Abstr Act (2009)
Genetic determinants of response to clopidogrel and cardiovascular events.The New England journal of medicine, 360 4
Plavix [package insert]
L. Laine, C. Hennekens (2010)
Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?The American Journal of Gastroenterology, 105
PiersonR,BansalP.U.S.judgeupholdsBristol,SanofipatentonPlavix.Reuters
Jersey Chen, Deepak Bhatt, E. Dunn, C. Shi, J. Caro, E. Mahoney, S. Gabriel, J. Jackson, E. Topol, D. Cohen (2009)
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 12 6
D. Angiolillo, A. Fernández-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. Bass, M. Costa (2007)
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.Journal of the American College of Cardiology, 49 14
T. Cuisset, C. Frère, J. Quilici, F. Barbou, P. Morange, T. Hovasse, J. Bonnet, M. Alessi (2006)
High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromeJournal of Thrombosis and Haemostasis, 4
(1999)
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE—CAPRIE Steering Committee and Investigators. clopidogrel versus aspirin in patients at risk of ischemic events
G. Montalescot, G. Sideris, C. Meuleman, Claire Bal-dit-Sollier, N. Lellouche, P. Steg, M. Slama, O. Milleron, J. Collet, P. Henry, F. Beygui, L. Drouet (2006)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.Journal of the American College of Cardiology, 48 5
C. Bennett, J. Connors, J. Carwile, J. Moake, W. Bell, S. Tarantolo, L. Mccarthy, R. Sarode, Amy Hatfield, M. Feldman, C. Davidson, H. Tsai, E. Michalets (2000)
Thrombotic thrombocytopenic purpura associated with clopidogrel.The New England journal of medicine, 342 24
Kurt Reinhart, C. White, W. Baker (2009)
Prasugrel: A Critical Comparison with ClopidogrelPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 29
M. Gilard, B. Arnaud, J. Cornily, G. Gal, K. Lacut, G. Calvez, J. Mansourati, D. Mottier, J. Abgrall, J. Boschat (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.Journal of the American College of Cardiology, 51 3
E. Becker, E. Rankin, A. Rickel (1998)
Guidelines for Prevention, I
Plavix label
SUMMARY: Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs. ABBREVIATIONS Act-Met active metabolite of clopidogrel ADP adenosine diphosphate AHA American Hospital Association GI gastrointestinal GPIIb/IIIa glycoprotein IIb/IIIa PPI proton pump inhibitor VWF von Willebrand factor
American Journal of Neuroradiology – American Journal of Neuroradiology
Published: Dec 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.